Ursolic Acid‐Loaded Iron‐MOF Nanomedicine Inhibits Lung Cancer Metastasis via JAK2/STAT3 Suppression and Ferroptosis
Advanced Healthcare Materials · 2026-06 · 15 (24)
DOI: 10.1002/adhm.202505496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 22.04.2026. Verfasst von Jiahui Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Triterpenes, Janus Kinase 2, Lung Neoplasms, STAT3 Transcription Factor. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Administration of Traditional Chinese Medicine, National Program for the Construction of Advantageous Traditional Chinese Medicine Specialties, National Science and Technology Major Project for Noncommunicable Chronic Diseases.
Abstract (Originalsprache)
Lung cancer metastasis is the primary cause of patient mortality, underscoring an urgent need for highly effective and low‐toxicity therapies. Ursolic acid (UA), a natural triterpenoid, possesses potent antitumor activity, yet its clinical translation has been hindered by poor water solubility, low bioavailability, and nonspecific distribution. To overcome these limitations, we developed a UA‐loaded iron‐based metal–organic framework (MOF) nanomedicine, termed Ursolic Acid‐loaded Iron‐MOF (UA@MOF). Harnessing the high surface area and tunable porosity of MOFs, this system enables efficient UA encapsulation and promotes tumor‐targeted delivery through the enhanced permeability and retention (EPR) effect. Once internalized, UA suppresses the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (JAK2/STAT3) signaling pathway, while iron ions released from the MOF induce ferroptosis in tumor cells via Fenton reactions. Together, these dual mechanisms act synergistically to inhibit tumor growth and metastasis. This work presents a novel strategy to improve the delivery and efficacy of natural antitumor agents, offering promising potential for the treatment of metastatic lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
ORCID-Profile: Zhanxia Zhang
Förderung
- National Administration of Traditional Chinese Medicine
- National Program for the Construction of Advantageous Traditional Chinese Medicine Specialties
- National Science and Technology Major Project for Noncommunicable Chronic Diseases
- Postoperative Adjuvant Chemotherapy in Driver Gene-Negative Early-to-Mid Stage Non-Small Cell Lung Cancer
- Clinical Research Project of the National Medical Center
- Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
- Shanghai New Three-Year Action Plan for Traditional Chinese Medicine Research
- Joint Research Project of the Health Commission of Pudong New Area
Zitieren
APA
Wang, J., Hou, W., Qiu, X., Zhang, Y., Tao, L., Chen, Y., Hong, B., Zhou, L., Li, H., & Zhang, Z. (2026). Ursolic Acid‐Loaded Iron‐MOF Nanomedicine Inhibits Lung Cancer Metastasis via JAK2/STAT3 Suppression and Ferroptosis. Advanced Healthcare Materials, 15(24). https://doi.org/10.1002/adhm.202505496
Vancouver
Wang J, Hou W, Qiu X, Zhang Y, Tao L, Chen Y, et al. Ursolic Acid‐Loaded Iron‐MOF Nanomedicine Inhibits Lung Cancer Metastasis via JAK2/STAT3 Suppression and Ferroptosis. Advanced Healthcare Materials. 2026;15(24). doi:10.1002/adhm.202505496
BibTeX
@article{Wang2026,
author = {Wang, Jiahui and Hou, Wanxin and Qiu, Xiuxiu and Zhang, Yu and Tao, Li and Chen, Yukun and Hong, Beibei and Zhou, Lei and Li, Hegen and Zhang, Zhanxia},
title = {Ursolic Acid‐Loaded Iron‐MOF Nanomedicine Inhibits Lung Cancer Metastasis via JAK2/STAT3 Suppression and Ferroptosis},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {24},
doi = {10.1002/adhm.202505496}
}
EUVIMED